Printer Friendly
The Free Library
14,558,602 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

Browse Antigens topic

Subtopics (13)

 

Articles

1-100 out of 100 article(s)
Title Author Type Date Words
ImmunoGen, Inc. Announces Conference Call to Discuss Clinical Data Reported at Recent Medical Meetings. Dec 3, 2009 258
Novel Intranasal Nanoemulsion Vaccine Adjuvant Also Effective by Subcutaneous and Intramuscular Injection. Dec 2, 2009 451
ImmunoGen, Inc. Announces Clinical Data Presentations on Three TAP Compounds at Upcoming ASH Annual Meeting and Exposition. Clinical report Nov 24, 2009 518
ImmunoGen, Inc. Announces Second License Taken by Amgen for Right to Use the Company's TAP Technology. Nov 19, 2009 431
ImmunoGen, Inc. Announces Encouraging Clinical Data with Its IMGN901 Compound in the Treatment of Merkel Cell Carcinoma. Nov 17, 2009 1171
ImmunoGen, Inc. Announces Election of Howard Pien to its Board of Directors and Other Results from its Annual Meeting of Shareholders. Nov 11, 2009 556
ImmunoGen, Inc. Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Conference news Nov 10, 2009 405
KSU researchers develop antigens. Nov 1, 2009 288
ImmunoGen, Inc. Announces Webcast of Presentation at the Oppenheimer 20th Annual Healthcare Conference. Conference news Oct 27, 2009 223
ImmunoCellular Therapeutics Applies for Key Patent Relating to Novel Antigen Targets for Its Monoclonal Antibody Product Candidate. Oct 19, 2009 786
NanoBio and the University of Michigan to Receive $9.3M from the NIH for Nanoemulsion-Based Vaccine Development. Oct 13, 2009 476
Advaxis Granted New Compositions and Methods Patent. Sep 23, 2009 784
ImmunoGen Announces Amgen has Licensed Rights to Use the Company's TAP Technology for a Solid Tumor Target. Sep 16, 2009 406
Celldex Therapeutics Announces Dosing of First Patient in Phase 1/2 Clinical Trial of its CDX-1401 Cancer Vaccine Candidate. Sep 14, 2009 960
ImmunoGen, Inc. Announces Webcast of Presentations at Two Investor Conferences. Conference news Sep 2, 2009 299
The U.S. National Institute of Health Awards Advaxis $210,000 for the Development of a Dual Antigen Vaccine. Aug 20, 2009 388
Advaxis to Collaborate with City of Hope. Aug 19, 2009 620
NanoBio to Present Preclinical Data on its Novel, Nanoemulsion-based Vaccine Adjuvant Platform at the Immunotherapeutics & Vaccine Summit. Aug 17, 2009 312
ImmunoGen, Inc. Announces Webcast of Presentation at the 29th Annual Canaccord Adams Global Growth Conference. Conference news Aug 5, 2009 224
ImmunoGen Announces Encouraging New Clinical Data with the Company's IMGN901 Compound in the Treatment of Small-Cell Lung Cancer. Aug 1, 2009 1689
United States : ImmunoGen Announces Encouraging New Clinical Data with the Company s IMGN901 Compound in the Treatment of Small-Cell Lung Cancer. Aug 1, 2009 460
Changes in the activated cytotoxic suppressor T-lymphocytes in elderly patients with mediterranean spotted fever. Gospodinova, Margarita D.; Nenova, Marina A.; Mileva, Sevda S. Report Jul 1, 2009 2906
Juvaris BioTherapeutics Announces Strategic Collaboration with Antigen Discovery, Inc. Jun 29, 2009 658
ImmunoGen, Inc. Announces Completion of Public Offering of Common Stock. Jun 23, 2009 291
New vaccine process proposed; Chemical, not biological method is fast. Jun 23, 2009 876
ImmunoGen, Inc. Announces Exercise of Over-allotment Option. Jun 22, 2009 442
ImmunoGen, Inc. Prices Public Offering of Common Stock. Jun 18, 2009 428
ImmunoGen, Inc. Announces Proposed Public Offering of Common Stock. Jun 17, 2009 386
Research and Markets: Vaccine Antigen Delivery Technologies - Molecular Systems to Open New Markets. Jun 12, 2009 407
ImmunoGen, Inc. Elects to Discontinue Further Internal Development of Its IMGN242 Compound. Jun 11, 2009 586
Advaxis Develops Innovative Approach in Cancer Mechanism Targeting. Jun 1, 2009 395
ImmunoGen, Inc. Announces Encouraging Trastuzumab-DM1 Phase II Clinical Findings Presented at ASCO. May 30, 2009 737
CSL Biotherapies Contracts with U.S. Department of Health and Human Services (HHS) to Provide Novel A (H1N1) Influenza Vaccine Antigen. May 29, 2009 413
Advaxis Receives US Patent and Trademark Office Approval on Act-A Protein Patent-Pending Rights. May 26, 2009 456
ImmunoGen, Inc. Announces Trastuzumab-DM1 Presentations at the 2009 American Society for Clinical Oncology Annual Meeting. May 14, 2009 621
Advaxis Scientific Founder Published in Prestigious Peer-Reviewed Journal of Immunology. May 11, 2009 682
Research and Markets: Therapeutic Cancer Vaccines - Evolving Strategies and Pipeline Prospects Revealed. May 7, 2009 345
Advaxis Applies for Approximately $5.0 Million in Grants in Response to U.S. Department of Defense Solicitation. May 4, 2009 668
Dynavax Presents Data From Novel Universal Flu Vaccine Candidate. Apr 30, 2009 790
Experts Available to Discuss: US Responding as If Swine Flu Will Be Pandemic. Apr 28, 2009 917
Advaxis Applies for Approximately $1.0 Million Worth of Grants from the National Institute of Health. Apr 27, 2009 489
NanoBio Initiates FDA Approved Clinical Trial for Adjuvanted Intranasal Influenza Vaccine. Apr 20, 2009 578
ImmunoGen, Inc. Announces Presentations at the American Association for Cancer Research Annual Meeting. Apr 10, 2009 649
VGX Pharmaceuticals Announces Agreement With the PATH Malaria Vaccine Initiative. Mar 23, 2009 385
ImmunoGen, Inc. Announces Webcast of Presentation at the Barclays Capital Global Healthcare Conference. Conference news Mar 3, 2009 208
ImmunoGen, Inc. Earns Milestone Payment with Genentech's Start of Trastuzumab-DM1 (T-DM1) Phase III Clinical Testing; Other T-DM1 Progress Reported. Mar 2, 2009 498
A closer look at asthma, part II. Wojciechowski, Bill Mar 1, 2009 1227
VGX Pharmaceuticals Avian Influenza DNA Vaccine Delivered with Electroporation Provides 100% Protection of Non-Human Primates. Feb 23, 2009 753
ImmunoGen, Inc. Announces Webcast of Presentation at the BIO CEO & Investor Conference 2009. Conference news Feb 2, 2009 191
ImmunoGen, Inc. Announces Webcast of its Investment Community Meeting on February 27, 2009. Jan 28, 2009 210
IAVI and Algonomics to Collaborate on HIV Protein Design Project. Jan 26, 2009 964
Advaxis Files 8-K on European Patent Appeal. Jan 16, 2009 569
Advaxis Prevails in European Patent Court. Jan 14, 2009 755
ImmunoGen, Inc. Announces Webcast of Presentation at the 27th Annual J.P. Morgan Healthcare Conference. Conference news Jan 8, 2009 174
ImmunoGen, Inc. Announces Favorable IMGN901 Clinical Findings Reported at ASH Annual Meeting. Clinical report Dec 9, 2008 771
ImmunoGen, Inc. Announces Genentech's Fifth TAP Technology License. Dec 8, 2008 352
Allergic bronchopulmonary aspergillosis in patients with moderate and severe asthma/ Orta ve agir astimli olgularda Alerjik bronkopulmoner aspergilloz. Aydogan, Oznur; Erdinc, Munevver; Aytemur, Zeynep Ayfer; Sin, Aytul; Savas, Recep Report Dec 1, 2008 3398
ImmunoGen, Inc. Announces Webcast of Presentation at the Lazard Capital Markets 5th Annual Healthcare Conference. Conference news Nov 11, 2008 191
ImmunoGen, Inc. Earns $4 Million Milestone Payment with sanofi-aventis' Initiation of a Phase II Trial with AVE1642. Oct 27, 2008 260
ImmunoGen, Inc. Announces Webcast of Presentation at the 7th Annual BioInvestor Forum. Oct 23, 2008 187
ImmunoGen, Inc. Announces Bayer HealthCare Has Licensed Rights to TAP Technology for a Solid Tumor Target. Oct 21, 2008 386
Argos Therapeutics Publishes Approach to Generating High-Avidity Cytotoxic T Cells with Dendritic Cell-Based Immunotherapy. Oct 21, 2008 593
ImmunoGen, Inc. Announces Presentations at Upcoming EORTC-NCI-AACR Symposium. Oct 14, 2008 415
ImmunoCellular Therapeutics Announces Filing of Patent Application for a Novel Cancer Stem Cell Vaccine Technology. Oct 9, 2008 621
Application of prostate-specific antigen in prostate cancer. Liang, Shu-Ling Oct 1, 2008 2599
ImmunoGen, Inc. Announces CEO Succession Plan. Sep 30, 2008 526
VaxInnate's Second Flu Vaccine Candidate Enters Clinical Development; Results Expected in Early 2009. Sep 30, 2008 818
ImmunoGen, Inc. to Present at Upcoming Investor Conferences. Conference news Sep 29, 2008 217
Emergent BioSolutions Notified by HHS That Its Proposal to Provide 25 Million Doses of Its Recombinant Anthrax Vaccine Is Technically Acceptable and Within the Competitive Range. Sep 12, 2008 794
Immunizing antigens and constituents of vaccines/Bagisiklik antijenleri ve asi icerigi. Keser, Melike; Hatipoglu, Nevin Sep 1, 2008 5836
ImmunoGen, Inc. Announces Webcast of Presentation at the Thomas Weisel Partners Healthcare Conference 2008. Conference news Aug 27, 2008 178
EndoBiologics, Incorporated, and PATH Form New Collaboration to Research Vaccine Candidates Against Diarrheal Disease. Aug 19, 2008 389
ImmunoGen, Inc. Announces sanofi-aventis Licenses Expanded Access to the Company's TAP Technology. Aug 12, 2008 414
United States: PharmAthene Submits Response to DHHS Request for Proposals for SparVax(TM). Aug 1, 2008 358
United States : Emergent BioSolutions Submits Proposal in Response to HHS RFP for Development and Procurement of a Recombinant Protective Antigen Anthrax Vaccine. Aug 1, 2008 1058
ImmunoGen, Inc. Announces Senior Management Promotions. Jul 31, 2008 583
Emergent BioSolutions Submits Proposal in Response to HHS RFP for Development and Procurement of a Recombinant Protective Antigen Anthrax Vaccine. Jul 31, 2008 1061
Chasing cancer; Vaccine may target deadly threats. Jul 9, 2008 894
ImmunoGen, Inc. Announces Start of IMGN388 Clinical Testing. Jul 7, 2008 542
A Shot in the Arm Against Breast Cancer. Jun 23, 2008 389
ImmunoGen, Inc. Raises $25.0 Million in Registered Direct Offering of Common Stock. Jun 23, 2008 268
Promising Data Presented on GenVec Malaria Vaccine Program. Jun 12, 2008 806
AVANT Announces Vaccine Adjuvant Licenses with 3M. Clinical report Jun 11, 2008 1402
ImmunoGen, Inc. Announces Presentation of Encouraging Clinical Findings with Trastuzumab-DM1 at ASCO. Jun 3, 2008 644
ImmunoGen, Inc. Announces Clinical Findings Reported at ASCO with Targeted Anticancer Compounds IMGN242 and AVE1642. Clinical report Jun 1, 2008 1290
ImmunoCellular Therapeutics Announces Ability to Characterize Distinct Antigens between Cancers Using Monoclonal Antibody Technology. May 28, 2008 732
Cytovance(R) Biologics Announces the Company is Providing Antibody cGMP Manufacturing for ImmunoGen, Inc. May 27, 2008 356
ImmunoGen, Inc. Announces Presentations at Upcoming 2008 American Society of Clinical Oncology Annual Meeting. May 23, 2008 407
Mymetics Corporation Acquires Preventive Malaria Vaccine From Pevion Biotech AG (Switzerland). May 19, 2008 913
VGX Pharmaceuticals announces filings of two separate INDs covering novel DNA vaccines: one for cervical cancer therapy (VGX-3100) and one for avian influenza (VGX-3400). Clinical report May 19, 2008 588
CSL Marks 40 Years in the Influenza Vaccine Market. May 13, 2008 584
ImmunoGen, Inc. Announces Webcast of Presentation at the 7th Annual JMP Securities Research Conference. Conference news May 12, 2008 194
Spain & United States: Emergent BioSolutions Acquires Advanced Recombinant Protective Antigen. May 6, 2008 403
Emergent BioSolutions Acquires Advanced Recombinant Protective Antigen Anthrax Vaccine Candidate and Technology. May 5, 2008 1259
Advaxis to Collaborate with City of Hope, a Leading Cancer Research and Treatment Center. Apr 17, 2008 910
ImmunoGen, Inc. Announces Presentations at the American Association for Cancer Research 2008 Annual Meeting. Apr 8, 2008 524
ImmunoGen, Inc. Announces Webcast of Presentation at the 8th Annual Fortis Biotechnology Conference. Conference news Mar 27, 2008 200
Role of MIP1a in Anti-Tumor Immunity and Therapy. Apr 1, 2000 1648
A Self-Replicating RNA Vaccine: More than Just Increased Copy Number. Mar 1, 2000 1301
New program predicts which peptides make good antigens. Jun 11, 1999 865

Terms of use | Copyright © 2009 Farlex, Inc. | Feedback | For webmasters | Submit articles